Clinical trial · Interventional
Metformin Versus Orlistat in Obese Polycystic Ovary Syndrome (PCOS) Patients
Orlistat Administration Facilitates the Obesity Treatment Among Obese PCOS Women
NCT01003483CI-TRIAL-00051008completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to compare the influence of Orlistat and Metformin on obesity treatment in obese PCOS women.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Obesity | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| orlistat | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Orlistat
- description
- The dose of 120 mg orlistat was taken three times daily and the dose remained constant throughout the study period.
- interventionNames
- Drug: orlistat
- type
- EXPERIMENTAL
- label
- Metformin
- description
- The dose of metformin was increased step - wise, from 500 mg once daily for the first week to 500 mg twice daily for the next week, and to 500 mg three times daily for the remaining study period .
- interventionNames
- Drug: orlistat
Primary outcomes (1)
- measure
- Body Mass Index (BMI)
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 40 Years
Show eligibility criteria text
Inclusion Criteria: * BMI\>= 30 * PCOS Exclusion Criteria: * Drug use during last three months
References
Publications (0)
Data not yet available
No reference posted for this study.